These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18752510)

  • 1. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
    Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
    Uusitalo H; Kaarniranta K; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():7-13. PubMed ID: 18752509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
    Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
    Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
    Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
    Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
    Erb C; Lanzl I; Seidova SF; Kimmich F
    Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.
    Chabi A; Baranak C; Lupinacci R; Herring WJ
    Int J Clin Pract; 2016 Jul; 70(7):577-86. PubMed ID: 27292765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients.
    Holló G; Hommer A; Antón López A; Ropo A
    J Ocul Pharmacol Ther; 2014 Aug; 30(6):468-75. PubMed ID: 24738883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
    Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY
    Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
    Traverso CE; Ropo A; Papadia M; Uusitalo H
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
    Aptel F; Choudhry R; Stalmans I
    Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.
    Oddone F; Tanga L; Kóthy P; Holló G;
    Adv Ther; 2020 Apr; 37(4):1436-1451. PubMed ID: 32072493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
    Swymer C; Neville MW
    Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
    Garcia-Medina JJ; Benitez-Del-Castillo J; Rodríguez-Agirretxe I; Lopez-Lopez F; Moreno-Valladares A;
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):252-260. PubMed ID: 35230148
    [No Abstract]   [Full Text] [Related]  

  • 18. Spanish multicenter tafluprost tolerability study.
    Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
    Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma.
    Egorov E; Ropo A;
    Eur J Ophthalmol; 2009; 19(2):214-22. PubMed ID: 19253237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.